Released
FY2026 Q1
Earnings ReviewMRK
MISS머크
Merck & Co., Inc. · 헬스케어 (제약·항암제)
Thu, April 30, 2026·Before Market Open
MerckKeytrudaCidaraOncologyHealthcarePatent cliff
01Wall Street Consensus
EPS$1.51
Revenue$15.82B
02Earnings Results
EPS$-1.28GAAP loss
Revenue$16.29B+3.0%
After-Hours ReactionRegular flat
Key Takeaways
- Revenue $16.29B — beat consensus $15.82B by +3%, +5% YoY
- Keytruda revenue $8.03B — beat consensus $7.78B by +3%, +12% YoY
- GAAP EPS -$1.28 — Cidara acquisition $3.62/sh charge
- Cidara Therapeutics acquisition closed — strengthens anti-infective pipeline
- FY2026 revenue guide raised to $65.8-67B (low end $65.5→$65.8B)
- FY2026 adj. EPS guide raised to $5.04-5.16 (from $5.00-5.15)
- Earlier-stage cancer indications powering Keytruda growth
- Solid metastatic-cancer demand
Key Checkpoints
- 01Keytruda revenue (~45% of total sales)
- 02Pipeline progress (Cidara acquisition)
- 03Preparing for the 2028 patent cliff — successor pipeline
- 04Ex-Keytruda revenue growth
- 05FY2026 guidance
Upside Catalysts
- Keytruda earlier-stage cancer expansion
- Cidara acquisition strengthens anti-infective pipeline
- Newer drug acceleration — Tukysa and others
Risk Factors
- Keytruda dependence — 2028 patent expiry
- Cidara acquisition one-off charge
- Variability of pipeline trial readouts
Detail
SEPS 서프라이즈 히스토리
Beat0Miss1Beat률 0%
분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출
컨센서스 대비 실제 EPS/매출 서프라이즈 (%)